Hematological Malignancy: Clinical Trials

1 trial for Hematological Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 unknown. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Unknown 1
Phase 21Unknown 1

Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents - Solid Tumor, Hematological Malignancy
Phase 1 / Phase 2UnknownChinese PLA General Hospital302019-09-152022-04-13

Narrower conditions

Cytokine Release Syndrome (1)  ·  Hematologic Neoplasms (1)

Broader conditions

Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Inflammation (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Shock (1)  ·  Systemic Inflammatory Response Syndrome (1)

Interventions

Etanercept (1)  ·  Infliximab (1)  ·  Metoprolol (1)

Sponsors

Chinese PLA General Hospital (1)

Countries

China (1)